Study with Reslizumab in Patients With Severe Eosinophilic Asthma
- Study Title
- A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
- Teva Identifier
- C38072-AS-30066 | 2016-004661-23
- ClinicalTrials.gov Identifier
- NCT03052725
- Study Status
- Terminated
- Trial Condition(s)
- Eosinophils, Asthma
- Interventions
- Drug: reslizumab
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult, Older Adult
- Age Range
- 12 Years and older
- Trial Duration
- March 10, 2017 - February 22, 2018
- Phase
- Phase 3
